Multicellular living organisms and unmodified parts thereof and – Method of making a transgenic nonhuman animal – Via microinjection of dna into an embryo – egg cell – or...
Reexamination Certificate
2002-11-22
2009-10-27
Chen, Shin-Lin (Department: 1632)
Multicellular living organisms and unmodified parts thereof and
Method of making a transgenic nonhuman animal
Via microinjection of dna into an embryo, egg cell, or...
C800S013000, C800S014000, C800S018000
Reexamination Certificate
active
07608750
ABSTRACT:
The present invention relates to provide a non-human animal model unresponsive to a synthetic compound wherein a gene function encoding TLR7 that recognizes an immunopotentiating synthetic compound such as imidazoquinoline lacks on is genomic locus. Whole or part of a gene fragment of a gene site including an intracellular region and a transmembrane region of a TLR7 gene obtained from a mouse gene library is replaced by a plasmid including poly A signal and a marker gene to construct a targeting vector. Then, this targeting vector is linearized and transferred into embryonic stem cells. The target embryonic stem cells wherein the TLR7 gene function is deleted are microinjected into a mouse blastocyst to generate a chimeric mouse. Then, this chimeric mouse is crossed with a wild-type mouse to generate a heterozygote mouse. Next, the heterozygote mice are intercrossed to obtain a TLR7 knockout mouse.
REFERENCES:
patent: 6943240 (2005-09-01), Bauer et al.
patent: WO 03/043572 (2003-05-01), None
Capecchi, Mario R., 1989, TIG, vol. 5, No. 3, p. 70-76.
Leonard et al., 1995, Immunological Reviews, vol. 148, pp. 97-114.
Rescher et al., 2004, Journal of Cell Science, vol. 117, p. 2631-2639.
Mogil et al., 1999, Pain, vol. 80, pp. 67-82.
Sigmund, C., Jun. 2000, Arterioscler. Thromb. Vasc. Biol., p. 1425-1429.
Tsung-Hsien Chuang et al., “Cloning and characterization of a sub-family of human Toll-like receptors: hTLR7, hTLR8 and hTLR9”, Eur. Cytokine Netw., Sep. 2000, pp. 372-378, vol. 11, No. 3.
Xin Du et al., “Three novel mammalian toll-like receptors: gene structure, expression, and evolution”, Eur. Cytokine Netw., Sep. 2000, pp. 362-371, vol. 11, No. 3.
Osamu Takeuchi et al., “Cutting Edge: Preferentially the T-Stereoisomer of the Mycoplasmal Lipopeptide Macrophage-Activating Lippopeptide-2 Activates Immune Cells Through a Toll-Like Receptor 2- and MyD88-Dependent Signaling Pathway”, The Journal of Immunology, Jan. 2000, pp. 554-557.
Gail A. Bishop et al., Molecular Mechanisms of B Lymphocyte Activation by the Immune Response Modifier R-848, The Journal of Immunology, 2000, pp. 5552-5557, vol. 165.
Hiroaki Hemmi et al., “Small Anti-Viral Compounds Activate Immune Cells Via the TLR7 My D88-Dependent Signaling Pathway”, Nature Immunology, vol. 3, No. 2, Feb. 2002, pp. 196-200.
Marion Jurk et al., “Human TLR7 or TLR8 Independently Confer Responsiveness to the Antiviral Compound R-848”, Nature Immunology, vol. 3, No. 6, Jun. 2002, p. 499.
Galli-Taliadoros, L.A., et al., (1995) Gene knock-out technology: a methodological overview for the interested novice, Journal of Immunological Methods, vol. 181, pp. 1-15.
Akira Shizuo
Tomizawa Hideyuki
Yamaoka Takashi
Chen Shin-Lin
Dainippon Sumitomo Pharma Co. ,Ltd.
Foley & Lardner LLP
Japan Science and Technology Agency
LandOfFree
Nonhuman model animal unresponsive to immunopotentiating... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Nonhuman model animal unresponsive to immunopotentiating..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Nonhuman model animal unresponsive to immunopotentiating... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4100168